HRMY - Harmony Corp Sales Growth YoY (Last Twelve Months)

Harmony Biosciences focuses on the therapy of narcolepsy and rare CNS pathologies while developing its R&D pipeline. Growth is driven by strategic alliances with laboratories and the acquisition of biotech startups. This chart of annual sales growth for the TTM confirms the trend, where the indicator level stands at 19.80. However, reliance on a single drug and patent expiration dates create significant risks for long-term business development.
Harmony Biosciences Inc (HRMY) - metric breakdowns and financial figures

For Harmony Biosciences (HRMY), which is shielded from competition by orphan drug status, the comparative year-over-year sales dynamics over a rolling period serve as an indicator of expansion efficiency within the rare disease market. This metric measures the percentage change in revenue over the last 12 months relative to the preceding year, allowing investors to assess business scaling rates and timely identify the asset's growth phase without the risk of overpaying.